Investigation of Bioterrorism-Related Anthrax, United States, 2001: Epidemiologic Findings

In October 2001, the first inhalational anthrax case in the United States since 1976 was identified in a media company worker in Florida. A national investigation was initiated to identify additional cases and determine possible exposures to Bacillus anthracis. Surveillance was enhanced through health-care facilities, laboratories, and other means to identify cases, which were defined as clinically compatible illness with laboratory-confirmed B. anthracis infection. From October 4 to November 20, 2001, 22 cases of anthrax (11 inhalational, 11 cutaneous) were identified; 5 of the inhalational cases were fatal. Twenty (91%) case-patients were either mail handlers or were exposed to worksites where contaminated mail was processed or received. B. anthracis isolates from four powder-containing envelopes, 17 specimens from patients, and 106 environmental samples were indistinguishable by molecular subtyping. Illness and death occurred not only at targeted worksites, but also along the path of mail and in other settings. Continued vigilance for cases is needed among health-care providers and members of the public health and law enforcement communities.

[1]  Interim guidelines for investigation of and response to Bacillus anthracis exposures. , 2001, MMWR. Morbidity and mortality weekly report.

[2]  Jerome Hauer,et al.  Anthrax as a biological weapon, 2002: updated recommendations for management. , 2002, JAMA.

[3]  M. Ferraro.  Performance standards for antimicrobial susceptibility testing , 2001 .

[4]  Sandra Romero-Steiner,et al.  Inhalational Anthrax Outbreak among Postal Workers, Washington, D.C., 2001 , 2002, Emerging infectious diseases.

[5]  M. Hugh-jones,et al.  The Sverdlovsk anthrax outbreak of 1979. , 1994, Science.

[6]  Sandra Romero-Steiner,et al.  Opening a bacillus anthracis-containing envelope, Capitol Hill, Washington, D.C.: the public health response. , 2002, Emerging infectious diseases.

[7]  Update: Investigation of bioterrorism-related anthrax--Connecticut, 2001. , 2001, MMWR. Morbidity and mortality weekly report.

[8]  P. Turnbull.  Definitive identification of Bacillus anthracis—a review , 1999, Journal of applied microbiology.

[9]  Jennifer L. Williams,et al.  Anthrax Postexposure Prophylaxis in Postal Workers, Connecticut, 2001 , 2002, Emerging infectious diseases.

[10]  A. Kaufmann,et al.  Inhalation anthrax in a home craftsman. , 1978, Human pathology.

[11]  Jeffrey P Koplan,et al.  Bioterrorism preparedness and response: clinicians and public health agencies as essential partners. , 2002, JAMA.

[12]  Aponte Deborah A. Adams Gerald Jones Willie J. Anderson D Connor,et al.  Update: Investigation of bioterrorism-related anthrax and interim guidelines for clinical evaluation of persons with possible anthrax. , 2001, MMWR. Morbidity and mortality weekly report.

[13]  M. Richardson,et al.  Update: Investigation of bioterrorism-related anthrax and adverse events from antimicrobial prophylaxis. , 2001, MMWR. Morbidity and mortality weekly report.

[14]  R. Brookmeyer,et al.  Prevention of Inhalational Anthrax in the U.S. Outbreak , 2002, Science.

[15]  Tanja Popovic,et al.  First Case of Bioterrorism-Related Inhalational Anthrax in the United States, Palm Beach County, Florida, 2001 , 2002, Emerging infectious diseases.

[16]  Gina Pugliese,et al.  Anthrax as a Biological Weapon: Medical and Public Health Management , 1999 .

[17]  Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. , 2001, MMWR. Morbidity and mortality weekly report.

[18]  Elizabeth R. Zell,et al.  Antimicrobial Postexposure Prophylaxis for Anthrax: Adverse Events and Adherence , 2002, Emerging infectious diseases.

[19]  N. Dakota..  Human anthrax associated with an epizootic among livestock--North Dakota, 2000. , 2001, MMWR. Morbidity and mortality weekly report.

[20]  H. Feldman.  Bacterial Infections of Humans , 1982, Springer US.

[21]  S. Plotkin,et al.  An epidemic of inhalation anthrax: the first in the twentieth century. II. Epidemiology. , 1960, American journal of hygiene.

[22]  T. Popović,et al.  Antimicrobial Susceptibility Testing of Bacillus anthracis: Comparison of Results Obtained by Using the National Committee for Clinical Laboratory Standards Broth Microdilution Reference and Etest Agar Gradient Diffusion Methods , 2002, Journal of Clinical Microbiology.

[23]  L. Rotz,et al.  Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices , 2001, Journal of toxicology. Clinical toxicology.

[24]  Tanja Popovic,et al.  Fatal inhalational anthrax in a 94-year-old Connecticut woman. , 2002, JAMA.

[25]  T. Popović,et al.  Suspected Cutaneous Anthrax in a Laboratory Worker—Texas, 2002 , 2002, MMWR. Morbidity and mortality weekly report.

[26]  Michael J. Beach,et al.  Surveillance for Anthrax Cases Associated with Contaminated Letters, New Jersey, Delaware, and Pennsylvania, 2001 , 2002, Emerging infectious diseases.

[27]  Tanja Popovic,et al.  Molecular Subtyping of Bacillus anthracis and the 2001 Bioterrorism-Associated Anthrax Outbreak, United States , 2002, Emerging infectious diseases.

[28]  K. Watanabe,et al.  [Inhalation anthrax]. , 1994, Ryoikibetsu shokogun shirizu.

[29]  Glenn F Webb,et al.  Mailborne transmission of anthrax: Modeling and implications , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Robert W Pinner,et al.  Bioterrorism alleging use of anthrax and interim guidelines for management--United States, 1998. , 1999, MMWR. Morbidity and mortality weekly report.

[31]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[32]  Update: Investigation of anthrax associated with intentional exposure and interim public health guidelines, October 2001. , 2001, MMWR. Morbidity and mortality weekly report.

[33]  C. P. Quinn,et al.  Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. , 2001, Emerging infectious diseases.

[34]  L. Price,et al.  Multiple-Locus Variable-Number Tandem Repeat Analysis Reveals Genetic Relationships within Bacillus anthracis , 2000, Journal of bacteriology.

[35]  Lilah M. Besser,et al.  Specific, Sensitive, and Quantitative Enzyme-Linked Immunosorbent Assay for Human Immunoglobulin G Antibodies to Anthrax Toxin Protective Antigen , 2002, Emerging infectious diseases.

[36]  L. Grummer-Strawn,et al.  Adherence to Antimicrobial Inhalational Anthrax Prophylaxis among Postal Workers, Washington, D.C., 2001 , 2002, Emerging infectious diseases.

[37]  B. Bell,et al.  Epidemiologic Investigations of Bioterrorism-Related Anthrax, New Jersey, 2001 , 2002, Emerging infectious diseases.

[38]  A. Monto,et al.  Epidemiology of viral respiratory infections , 2002, The American Journal of Medicine.

[39]  S. Plotkin,et al.  An epidemic of inhalation anthrax, the first in the twentieth century. I. Clinical features. , 1960, The American journal of medicine.

[40]  Philip K. Russell,et al.  Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. , 1999, JAMA.